Antidepressant drug use in glioblastoma patients: an epidemiological view

Gramatzki, Dorothee; Rogers, James Louis; Neidert, Marian Christoph; Hertler, Caroline; Le Rhun, Emilie; Roth, Patrick; Weller, Michael

Type de document :

Article dans une revue scientifique: Article original

DOI :

10.1093/nop/npaa022

PMID :

33014392

URL permanente :

http://hdl.handle.net/20.500.12210/75194

Titre :

Antidepressant drug use in glioblastoma patients: an epidemiological view

Auteur(s) :

Gramatzki, Dorothee [Auteur]
University hospital of Zurich [Zurich]
Rogers, James Louis [Auteur]
University hospital of Zurich [Zurich]
Neidert, Marian Christoph [Auteur]
University hospital of Zurich [Zurich]
Hertler, Caroline [Auteur]
University hospital of Zurich [Zurich]
Le Rhun, Emilie [Auteur]

Roth, Patrick [Auteur]
University hospital of Zurich [Zurich]
Weller, Michael [Auteur]
University hospital of Zurich [Zurich]

Titre de la revue :

Neuro-oncology practice

Nom court de la revue :

Neurooncol Pract

Numéro :

Pagination :

514-521

Éditeur :

Oxford University Press

Date de publication :

2020-10-01

ISSN :

2054-2577

Mot(s)-clé(s) :

glioblastoma
antidepressants
depression
epidemiology
survival

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized ...
Lire la suite >BACKGROUND: Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level. METHODS: Patient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons. RESULTS: A total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not (P = .356). These data were confirmed in a multivariate analysis including age, Karnofsky Performance Scale (KPS), sex, extent of resection, O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation status, and first-line treatment as cofounders (P = .315). Also, there was no association of use of drugs modulating voltage-dependent potassium channels (citalopram; escitalopram) with survival (P = .639). CONCLUSIONS: This signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

INSERM
Université de Lille

Collections :

Autres travaux scientifiques

Date de dépôt :

2022-06-15T13:59:53Z
2023-03-08T09:34:32Z
2023-04-21T10:12:46Z

Fichiers

2020-10-01-npaa022.pdf
Version éditeur
Accès restreint
Accéder au document

Historique des modifications

Numéro de version	Lien	Date de modification
3	20.500.12210/75194*	2023-04-21T10:12:27Z
2	20.500.12210/75194.2	2023-03-08T09:25:16Z
1	20.500.12210/75194.1	2022-06-15T13:59:53Z

*Version sélectionnée

Antidepressant drug use in glioblastoma ... BibTeX CSV Excel RIS

Fichiers

Historique des modifications

Antidepressant drug use in glioblastoma ...

BibTeX

CSV

Excel

RIS